Neurogene Inc.

NASDAQ : NGNE

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Information

Website
https://www.neurogene.com
Sector
Healthcare
Industry
Biotechnology
Type
Common Stock
Country
United States

Price

USD 40.50

Symbol

NGNE

Type

Common Stock

Previous Close

 :

40.75

52 Week Range

 :

12.49 - 53.00

Volume

 :

1,888,757.00

Average Volume

 :

306,966.00

High

 :

42.99

Low

 :

38.84

Change

 :

-0.25

Percent change (%)

 :

-0.61

Stakeville

A Free-to-Play Trading Game. Sharpen your skills, trade stocks, and have fun!

Play Now
Getting Started
Get Your Free Account For Educational Purpose Knowledgebase
Legal
Cookie Policy Privacy Policy Terms & Conditions
Customer Service
Help Desk Support Stakeville Newsletter
Stay Connected
Contact Us Official Blog About Us
Disclaimer: Stakeville is a simulation trading game. All trades and stock prices are fictional and do not reflect real-world markets. This game is for entertainment purposes only and does not involve real financial transactions. Read more...